Morningstar

Sartorius AG PRF PERPETUAL EUR SRT3

Morningstar Rating
Unlock
Stock XETR Rating as of
€251.00 −8.40 (3.24%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Sartorius Well Positioned To Benefit From Biopharma Industry Recovery

Max Jousma

Sartorius AG is a leading provider of bioprocessing equipment and consumables, offering a comprehensive portfolio that spans the full spectrum of upstream and downstream processes required for biologics manufacturing. Its ability to deliver end-to-end solutions, and its focus as a pure-play biopharmaceutical equipment supplier distinguish Sartorius AG from more diversified competitors. Sartorius AG further reinforces its competitive edge by leading the market in bioreactors, a core component of the biomanufacturing process.

Read Analysis

Price vs Fair Value

View History
SRT3 is trading at a LOCK|rcR#S< premium.
Price
€251.00
Fair Value
r^?
Uncertainty
LOCK|hyb
1-Star Price
LOCK|<.Kfj
5-Star Price
LOCK|j.@
Economic Moat
LOCK|J>Q
Capital Allocation
LOCK|#<@>NM

Bulls Say, Bears Say

Bulls

Sartorius AG’s product portfolio in CGT allows it to capitalize on long-term growth, should these therapies achieve widespread adoption.

Bears

The high growth in the biopharma market increases the risk of greater competition from better-capitalized peers who have a broader product offering.

Show More

Trading Information

Previous Close Price
€259.40
Day Range
€249.60–259.30
52-Week Range
€198.50–270.00
Bid/Ask
€0.00 / €0.00
Shares Outstanding
69.05M
Market Cap
€17.33B
Volume/Avg
82,357 / 94,560

Key Statistics

Price/Earnings (Normalized)
77.79
Price/Sales
5.01
Dividend Yield (Trailing)
0.29%
Dividend Yield (Forward)
0.29%
Dividend Payment Schedule
Mar
Total Yield
0.29%

Company Profile

Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Sector
Healthcare
Industry
Medical Instruments & Supplies
Stock Style Box
Large Growth
Total Number of Employees
14,279
Website
https://www.sartorius.com

Competitors

Valuation

View More
Metric
SRT3
MRK
MTD
Price/Earnings (Normalized)
 77.7917.1233.00
Price/Book Value
 6.351.992,314.40
Price/Sales
 5.012.847.30
Price/Cash Flow
 25.3813.1928.15
Price/Earnings
SRT3
MRK
MTD

Financial Strength

Metric
SRT3
MRK
MTD
Quick Ratio
 0.480.990.65
Current Ratio
 1.141.691.12
Interest Coverage
 3.667.2216.83
Quick Ratio
SRT3
MRK
MTD

Profitability

Metric
SRT3
MRK
MTD
Return on Assets (Normalized)
 3.06%4.75%26.25%
Return on Equity (Normalized)
 10.99%8.32%—
Return on Invested Capital (Normalized)
 4.84%6.65%48.46%
Return on Assets
SRT3
MRK
MTD

Medical Instruments & Supplies Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Intuitive Surgical Inc
ISRG
LOCK|%?QW!$c^LOCK|NY?$142B
 Becton Dickinson & Co
BDX
LOCK|jJBLOCK|$RcN$49B
 ResMed Inc
RMD
LOCK|g>!>y&YLOCK|$F^G@$32B
 Medline Inc Ordinary Shares - Class A
MDLN
LOCK|KjJRKbLOCK|<@$BV$31B
 Alcon Inc
ALC
LOCK|T&N@dmLOCK|dL<q$31B
 West Pharmaceutical Services Inc
WST
LOCK|N$c@<D?sLOCK|Fy$26B
 Solventum Corp
SOLV
LOCK|WD@LSsLOCK|BT$15B
 Baxter International Inc
BAX
LOCK|NgLOCK|$&%$$12B
 The Cooper Companies Inc
COO
LOCK|Smjxh#LOCK|J<xWL$11B
 Align Technology Inc
ALGN
LOCK|nsrSG>LOCK|!%?P!$10B

Sponsor Center